Skip to main content

Table 1 Baseline characteristics of responders and non-responders, split for treatment received

From: Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?

Item ADA (n = 60) ETN (n = 60)
  Non-resp Resp p value Non-resp Resp p value
  (n = 30) (n = 30)   (n = 30) (n = 30)  
Female gender, n (%) 21 (70) 21 (70) 1.00 25 (83) 21 (70) 0.36
Age, mean years ± sd 54.4 ± 10.9 53.5 ± 12.7 0.76 58.3 ± 9.2 55.1 ± 10.5 0.22
Current smoker, n (%) 16 (53) 8 (27) 0.06 8 (27) 7 (23) 1.00
RF positivity, n (%) 16 (53) 21 (70) 0.29 20 (67) 22 (73) 0.78
ACPA positivity, n (%) 19 (63) 19 (63) 1.00 19 (63) 26 (87) 0.07
CRP, mg/l median (IQR) 5.2 (1.6–10.5) 5.5 (2.0–12.3) 0.78 4.0 (2.0–9.0) 8.5 (4.0–18.3) 0.03
No. of previously used bDMARDs       1.00
 0, n (%) 20 (67) 23 (78)   22 (73) 22 (73)  
 1, n (%) 9 (30) 7 (23)   7 (23) 7 (23)  
 2, n (%) 1 (3) 0 (0)   1 (3) 1 (3)  
Concomitant treatment, n (%) 29 (97) 29 (97) 1.00 27 (90) 29 (97) 0.61
 MTX, n (%) 21 (70) 27 (90) 0.10 18 (60) 25 (83) 0.08
 SSZ, n (%) 2 (7) 4 (13) 0.67 4 (13) 2 (7) 0.67
 HCQ, n (%) 8 (27) 7 (23) 1.00 10 (33) 11 (37) 1.00
 GC, n (%) 15 (50) 4 (13) 0.01 11 (37) 6 (20) 0.25
Baseline DAS28, mean ± sd 3.9 ± 1.4 4.7 ± 0.9 0.01 4.3 ± 1.2 4.6 ± 0.9 0.21
 TJC, median (IQR) 5.0 (1.0–13.0) 7.0 (4.0–14.3) 0.35 6.5 (2.8–11.3) 5.0 (2.8–11.3) 0.87
 SJC, median (IQR) 0.0 (0.0–4.0) 2.0 (0.0–4.0) 0.03 1.0 (0.0–3.3) 2.0 (0.8–4.0) 0.20
 VAS-GH, mean ± sd 55.2 ± 23.8 63.8 ± 22.0 0.15 55.5 ± 22.8 55.1 ± 10.5 0.76
 ESR, median mm/hr (IQR) 11.0 (3.8–26.0) 16.5 (9.0–32.0) 0.14 13.0 (5.8–33.8) 21.0 (14.3–39.5) 0.07
  1. RA patients were selected from the observational BiOCURA cohort based on treatment outcome over the course of 1 year after the start of treatment with either ADA or ETN. The presented clinical characteristics for responders and non-responders refer to the values present before treatment initiation. P values of comparisons between responders and non-responders were calculated by means of an independent sample t test, Mann-Whitney U test, Fisher’s exact test (2*2) or chi-square (>2*2) based on the distribution of the clinical parameter. Bold p values indicate significant associations (p < 0.05)
  2. ACPA anti-citrullinated protein antibody, ADA adalimumab, bDMARDs biological disease-modifying antirheumatic drugs, CRP C-reactive protein, ESR erythrocyte sedimentation rate, ETN etanercept, GC glucocorticoid, HCQ hydroxychloroquine, IQR interquartile range, MTX methotrexate, RF rheumatoid factor, SJC swollen joint count, SSZ sulfasalazine, TJC tender joint count, VAS-GH visual analogue scale of general health